After Biogen exit, Mitsubishi Tanabe Pharma links up with Salix to develop amiselimod; Two drug developers set up antibiotic collaboration

→ About two years after Biogen $BIIB walked away from Mitsubishi Tanabe Pharma‘s MT-1303 (amiselimod), the Japanese drugmaker has joined forces with Bausch Health’s Salix Pharmaceuticals to develop the late-stage oral compound, which targets the sphingosine 1-phosphate (S1P) receptor that is understood to play a role in autoimmune diseases, such as IBD and ulcerative colitis. Financial details of the deal were not disclosed.

→ While the biopharma world struggles to keep new antibiotic makers afloat, two drug developers are forging a pact to develop inhibitors against two “historically difficult-to-drug, unexploited antibiotic targets.” Forge Therapeutics and Switzerland’s Basilea Pharmaceutica have inked a research collaboration and license agreement to discover, develop, and commercialize fresh antibiotic classes, using Forge’s BLACKSMITH platform.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 50,700+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->